Equities

GeoVax Labs Inc

GeoVax Labs Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.98
  • Today's Change-0.03 / -1.49%
  • Shares traded29.00
  • 1 Year change-75.65%
  • Beta3.1042
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

  • Revenue in USD (TTM)300.68k
  • Net income in USD-26.92m
  • Incorporated2008
  • Employees17.00
  • Location
    GeoVax Labs Inc1900 Lake Park Drive, Suite 380SMYRNA 30080United StatesUSA
  • Phone+1 (678) 384-7220
  • Fax+1 (302) 655-5049
  • Websitehttps://www.geovax.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evaxion Biotech A/S - ADR278.00k-15.21m15.84m49.00--12.26--56.96-36.98-36.980.10480.23160.0174--0.34935,673.47-95.08-100.11-126.11-131.65-----5,469.42-131,560.30----0.8933------4.51--65.53--
NRX Pharmaceuticals Inc0.00-24.83m15.91m2.00---------1.62-1.620.00-1.700.00-------197.97-120.57---168.40-----------189.12--------24.14------
Cognition Therapeutics Inc0.00-31.08m16.05m25.00--0.6973-----0.9317-0.93170.000.57360.00----0.00-79.36---104.49-------------263.290.00-------20.52------
Athira Pharma Inc0.00-113.45m16.25m65.00--0.195-----2.97-2.970.002.170.00----0.00-71.06-30.73-83.81-32.46------------0.00-------23.04------
Mira Pharmaceuticals Inc0.00-12.78m16.26m3.00--7.33-----0.8562-0.85620.000.15010.00----0.00-373.77---737.47-------------3.170.00-------69.77------
OpGen Inc1.96m-22.39m16.29m100.00------8.29-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Matinas BioPharma Holdings Inc0.00-22.91m16.50m32.00--0.8639-----5.10-5.100.003.810.00----0.00-78.48-44.62-85.80-48.25-------2,344.60----0.001---65.6255.71-9.26---16.46--
AIM ImmunoTech Inc201.00k-28.05m16.59m26.00--2.45--82.54-0.5703-0.57030.0040.10680.0082--12.187,730.77-113.70-45.64-149.16-48.3571.14-231.75-13,952.74-11,695.01----0.3018--43.26-11.26-48.94--35.73--
Microbot Medical Inc0.00-10.44m16.83m22.00--2.69-----0.81-0.810.000.37930.00----0.00-113.94-53.28-133.34-62.65------------0.00------18.44---31.76--
Geovax Labs Inc300.68k-26.92m16.88m17.00------56.14-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
Biomx Inc0.00-26.25m17.00m58.00---------0.4575-0.45750.000.39290.00----0.00-47.79---57.76--------------0.00------7.59------
Palatin Technologies, Inc.4.49m-29.74m17.02m30.00------3.79-1.97-1.970.2981-0.00620.31310.37133.08149,669.70-207.35-55.28-1,527.99-69.0897.83---662.26-1,359.141.01-------7.49-40.52-23.71--3.31--
Impact Biomedical Inc0.00-4.25m17.25m1.00--0.7399-----0.3694-0.36940.002.030.00----0.00-9.59---15.04-------------5.120.3377---100.00--38.51------
Synlogic Inc3.17m-56.16m17.54m6.00--1.10--5.53-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Bioxytran Inc0.00-3.51m17.80m2.00---------0.023-0.0230.00-0.00230.00-------2,635.88-1,420.53---------------20.68---------73.71------
MEI Pharma Inc65.30m17.78m18.06m28.001.020.54680.99420.27652.672.679.804.960.8052--1,536.402,332,036.0021.92-21.0926.64-23.99----27.23-72.23----0.00--33.7667.75155.84---49.68--
Data as of Oct 08 2024. Currency figures normalised to GeoVax Labs Inc's reporting currency: US Dollar USD

Institutional shareholders

9.63%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 2024178.00k7.04%
BlackRock Fund Advisorsas of 31 Mar 202427.57k1.09%
The Vanguard Group, Inc.as of 31 Mar 202419.24k0.76%
Geode Capital Management LLCas of 30 Jun 202413.87k0.55%
Tower Research Capital LLCas of 31 Mar 20244.47k0.18%
Wells Fargo Clearing Services LLCas of 31 Mar 2024134.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024120.000.01%
Wells Fargo Advisors Financial Network LLCas of 31 Mar 202467.000.00%
Global Retirement Partners LLCas of 30 Jun 202427.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202416.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.